Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET

Company Participants

Michael Wood - LifeSci Advisors

Chaim Lebovits - President and CEO

Stacy Lindborg - EVP and Chief Development Officer

Ralph Kern - President and Chief Medical Officer

Alla Patlis - Interim CFO

Conference Call Participants

David Bautz - Zacks Small-Cap

Daniel Walker - Ness Industries

Operator

Greetings, and welcome to the Brainstorm Cell Therapeutics Third Quarter 2022 Conference Call. At this time, participants are in a listen-only mode. As a reminder, this conference call is being recorded.

And now, I would like to introduce your host for today's conference, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood

Good morning and thank you for joining us. Before we begin the call - opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative orders, such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time-to-time in the company's SEC filings. The company's results may differ materially from those projected on today's call and the company undertakes no obligation to publicly update any forward-looking statements.

Joining me on the call today will be Chaim Lebovits, President and CEO of Brainstorm; Dr. Stacy Lindborg, Executive Vice President and Chief Development Officer; Dr. Ralph Kern, President and Chief Medical Officer; and Alla Patlis, Interim Chief Financial Officer. In addition, Dr. David Setboun, Executive Vice President and Chief Operating Officer is also on the call and will be available to answer your questions during the Q&A session.

So now, I would like to turn the call over to Mr. Lebovits. Please go ahead.

Chaim Lebovits

Thanks Michael, and thank you to everyone for joining us this morning.

As is our usual practice, we'll follow our prepared remarks by addressing questions we received from investors in advance, as well as taking live questions from those of you listening on the call today.